Abstract
The aim of the study was to analyze the factors influencing peripheral blood progenitor cell (PBPC) collection after high-dose cyclophosphamide (HDCYC) (7 g/m2) and hematopoietic recovery after autologous transplantation of HDCYC-mobilized PBPC (ABPCT) in 116 patients with aggressive multiple myeloma (MM). Following HDCYC 74 patients received hematopoietic growth factors (HGF), either G-CSF (n = 19) or GM-CSF (n = 55). All the patients were subsequently planned to undergo ABPCT. PBPC collection was possible for 106 patients. The most important prognostic factor for collection of more than 25 × 104 CFU-GM cells/kg and 2 × 106 CD34+ cells/kg was the use of HGF (P = 0.002 and 0.009, respectively). Previous use of an alkylating agent, response to treatment before HDCYC, and interval between diagnosis and HDCYC were also significant factors (P = 0.004, 0.025 and 0.001, respectively). The number of CFU-GM cells infused was the most important parameter for rapid and complete hematological recovery after ABPCT (P < 0.0001). thus the use of hgf post-hdcyc is the major factor which, associated with reduced time between diagnosis and hdcyc and the use of an alkylating agent, could increase the numbers of hematopoietic progenitors collected, and subsequently improve hematopoietic recovery following abpct in mm patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marit, G., Thiessard, F., Faberes, C. et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 12, 1447–1456 (1998). https://doi.org/10.1038/sj.leu.2401105
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401105
Keywords
This article is cited by
-
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma
Bone Marrow Transplantation (2010)
-
Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions
Bone Marrow Transplantation (2009)
-
The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients
Bone Marrow Transplantation (2006)
-
Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization
Bone Marrow Transplantation (2006)
-
Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis
Annals of Hematology (2006)